Skip to main content

Definium Therapeutics, Inc. (DFTX) Stock

Definium Therapeutics, Inc. Stock Details, Movements and Public Alerts

Stock Details

Definium Therapeutics, Inc. (DFTX), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $44.84. Over the past 52 weeks, it has ranged between $8.70 and $49.70. This places the current price at 90.2% of its 52-week high and 415.4% above its 52-week low. Recent trading volume was recorded at 1,473,727. The 14-day Relative Strength Index (RSI) stands at 50.93, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $38.62 by 16.11%. Similarly, it is above its 200-day moving average of $22.35 by 100.63%. The MACD histogram is -0.52, indicating bearish momentum (MACD Line: 1.00, Signal Line: 1.52). There is currently 1 active alert set for DFTX by users.

52-Week Range

$49.70 - $8.70

-9.78% from high · +415.40% from low

Avg Daily Volume

2,140,834

20-day average

100-day avg: 2,553,359

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-25.24

Price to Book

6.26

EPS (TTM)

-$3.43

Beta

2.26

More volatile than market

Q:How is DFTX valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is DFTX's risk profile compared to the market?
With a beta of 2.26, Definium Therapeutics, Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 23% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 6.26 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

Return on Equity

-64.09%

Return on Assets

-20.64%

Q:How profitable and efficient is DFTX's business model?
Profitability metrics are not available for this stock.
Q:What are DFTX's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$5.7B

Shares Outstanding

132.74M

Book Value/Share

$6.84

Asset Type

EQUITY

Q:What is DFTX's market capitalization and position?
Definium Therapeutics, Inc. has a market capitalization of $5.7B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 132.74M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does DFTX's price compare to its book value?
Definium Therapeutics, Inc.'s book value per share is $6.84, while the current stock price is $44.84, resulting in a price-to-book (P/B) ratio of 6.56. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$60.13

34.11% upside potential

Analyst Recommendations

Strong Buy

4

Buy

11

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for DFTX?
15 analysts cover DFTX with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $60.13 implies 34.1% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on DFTX?
Current analyst recommendations:4 Strong Buy, 11 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Aug 13, 2026, 02:23 AM

Technical Indicators

RSI (14-day)

50.93

Neutral

50-Day Moving Average

$38.62

16.11% above MA-50

200-Day Moving Average

$22.35

100.63% above MA-200

MACD Line

1.00

MACD Signal

1.52

MACD Histogram

-0.52

Bearish

Q:What does DFTX's RSI value tell investors?
The RSI (Relative Strength Index) for DFTX is currently 50.93, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret DFTX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 1.00 below the signal line at 1.52, with histogram at -0.52. This bearish crossover indicates downward pressure. The 50-day MA ($38.62) is above the 200-day MA ($22.35), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Aug 13, 2026, 01:41 PM

Active Alerts

Alert Condition
Price decreases by
Threshold
10%
Created
Jul 27, 2026, 04:16 PM

Stay Ahead of the Market with Definium Therapeutics, Inc. Alerts

Set up price alerts for Definium Therapeutics, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.